According to a recent LinkedIn post from Beacon Therapeutics, CEO Lance Baldo recently appeared on the Base to Base Biotech podcast to discuss the company’s efforts in treating inherited retinal diseases, including X-linked retinitis pigmentosa. The discussion reportedly focused on the goal of saving and restoring vision through gene therapy approaches and advancing the lead program laru-zova toward commercialization.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also highlights Beacon Therapeutics’ recently completed oversubscribed $75M Series C financing, led by Life Sciences at Goldman Sachs Alternatives, which is intended to fund laru-zova and broader pipeline progress. For investors, the successful raise and focus on late-stage development suggest growing institutional confidence in the company’s ophthalmology platform, though eventual returns will depend on clinical outcomes, regulatory milestones, and commercialization execution in the rare disease gene therapy space.